Omnix Medical has dosed the first patients in a randomized, placebo-controlled Phase IIa trial of OMN6, a cyclized 40-residue analog of the moth peptide Cecropin A, in hospital-acquired and ventilator-associated pneumonia caused by carbapenem-resistant Acinetobacter baumannii. A roughly €8 million…
Omnix Medical has dosed the first patients in a randomized, placebo-controlled Phase IIa trial of OMN6 , a cyclized 40-residue peptide derived from the moth antimicrobial peptide Cecropin A , for hospital-acquired and ventilator-associated pneumonia caused by carbapenem-resistant Acinetobacter baumannii CRAB . The first patients were dosed in June 2026 at Israeli medical centers, and the study is registered as NCT06087536. In 2026, Horizon Europe , the European Union's flagship research program, awarded roughly €8 million approximately $9.15 million to the OMN6 consortium to accelerate clinical development, speed patient recruitment, and move the program toward Phase III.
The dosing marks the first time a stabilized, cyclized analog of one of the founding antimicrobial peptides has entered randomized, placebo-controlled human testing. Cecropin A was isolated in the early 1980s by Hans G. Boman and colleagues at Stockholm University from pupae of the giant silk moth Hyalophora cecropia , and its sequence and specificity were published in 1981 in Nature by Steiner, Hultmark, Engström, Bennich, and Boman. That work established the concept that animals defend themselves with gene-encoded antibacterial peptides. For four decades, turning such peptides into drugs has failed repeatedly, most often on rapid proteolytic degradation, toxicity, and the expense of manufacturing.
The clinical target explains the urgency. CRAB is ranked by the WHO as a critical-priority pathogen, and mortality in vulnerable patients can approach 60%. OMN6 is now being tested against that organism in human beings, and the result will carry meaning for the entire antimicrobial peptide field, not just one molecule.
OMN6 has attracted two EU-funded initiatives. The 2026 Horizon Europe award follows the participation of the European Innovation Council Fund in Omnix Medical's $25 million Series C, a round announced in October 2025 via GlobeNewswire and co-led by Harel Insurance & Finance and the EIC Fund. Equity from a private insurer and a public innovation fund, layered with a non-dilutive EU grant, gives the program the means to run a controlled pneumonia trial and to plan the manufacturing scale-up that Phase III would require.
Omnix Medical was founded in Jerusalem in 2015 by Dr. Moshik Cohen-Kutner and Dr. Niv Bachnoff. Cohen-Kutner, the chief executive officer and a co-founder, holds a doctorate in molecular and structural biochemistry from the Hebrew University of Jerusalem and came out of peptide design and peptide-based drug discovery. Bachnoff, the chief scientific officer and a co-founder, completed doctoral work at the Hebrew University of Jerusalem. OMN6 is the company's lead clinical candidate.
The advisory boards are notable for a company of this size. Roger D. Kornberg of Stanford University, winner of the 2006 Nobel Prize in Chemistry for work on the molecular basis of eukaryotic transcription, sits on the scientific advisory board. The medical and clinical advisory board includes Yehuda Carmeli of Tel Aviv Sourasky Medical Center, an expert in antimicrobial-resistance epidemiology, and Keith Kaye of Rutgers Robert Wood Johnson Medical School. Carmeli and Kaye have spent their careers on exactly the problem this trial addresses: designing studies and stewardship programs for infections caused by carbapenem-resistant Gram-negative bacteria.
The trial, NCT06087536, enrolls patients with hospital-acquired or ventilator-associated bacterial pneumonia caused by CRAB, and the first patients were dosed at Israeli medical centers in June 2026. Omnix has not disclosed the sample size, the treatment duration, or the study endpoints, and no efficacy or safety results have been reported.
The design matters. Randomization and placebo control are not the historical default in early antimicrobial peptide research, much of which has relied on open-label cohorts and descriptive safety reporting. A controlled comparison is particularly valuable in pneumonia, where the diagnosis is partly clinical, microbiological confirmation is imperfect, and outcomes are strongly influenced by the patient's condition at enrollment. A randomized, blinded design allows a small Phase IIa study to separate a drug effect from the noise of a heterogeneous, severely ill population.
What a Phase IIa can deliver is an early signal: acceptable safety in the target population and a read on whether the peptide does something measurable in patients. What it cannot deliver is a mortality claim, which belongs to a larger, event-driven Phase III, nor can it test the hypothesis that membrane disruption limits the evolution of resistance. Resistance emergence is a population-level phenomenon that plays out over repeated exposures and long treatment courses, not within the window of a Phase IIa.
A placebo-controlled design in a disease that can kill roughly 60% of vulnerable patients also demands a protocol that preserves access to standard antibiotic therapy in both arms. Omnix has not stated what background treatment the trial allows, and that is a disclosure gap the field will want closed before interpreting results.
OMN6 is a 40-residue cyclic peptide, closed through a disulfide bond between terminal cysteine residues. It was first described in 2021 in Scientific Reports by Mandel and colleagues as a cyclized Cecropin A analog, and its in vitro and in vivo activity against multidrug-resistant A. baumannii was published in 2022 in the journal Antibiotics . The cyclization dramatically slows proteolytic degradation of OMN6 while preserving the membrane-disrupting amphipathic alpha-helix. The chemistry is straightforward to explain: exopeptidases attack free amino and carboxy termini, a cyclic peptide has none, and the disulfide closure holds the helix in its active conformation.
The mechanism of Cecropin A is physical. The amphipathic helix presents a hydrophobic face that inserts into the lipid bilayer and a cationic face that engages the negatively charged phospholipids concentrated in bacterial membranes. The peptide kills Gram-negative bacteria by inserting into and disrupting the bacterial membrane, a non-enzymatic process that is thought to make classical resistance difficult to evolve. That is a hypothesis, and the Phase IIa will not test it; the evidence for it comes from in vitro and animal studies.
The published preclinical data describe a Gram-negative-selective agent. OMN6 showed minimum inhibitory concentrations in the low single-digit µg/mL range against multidrug-resistant and colistin-resistant A. baumannii, no meaningful activity against Gram-positive bacteria, and no cytotoxicity or hemolysis against human cells at the concentrations tested. The selectivity pattern is consistent with the proposed mechanism: the peptide engages molecular features of the Gram-negative cell envelope, and the absence of hemolysis is consistent with a peptide that distinguishes bacterial membranes from the mostly zwitterionic membranes of human cells.
The contrast between the molecule's age and its chemical novelty is the point. Cecropin A has been studied since the early 1980s; what is new is not the founding peptide but the stabilization of it. The field's repeated failures came largely from delivering linear peptides that were destroyed before reaching the infection site, or that damaged host tissues at effective doses. Cyclization addresses the first failure mode directly, and the preclinical toxicity data address the second.
For peptide researchers, the program is a test of a simple engineering idea. If OMN6's Phase IIa results match its preclinical profile, disulfide cyclization will have demonstrated that a four-decade-old stability problem can be solved without elaborate chemistry, and the strategy becomes an obvious candidate for other natural antimicrobial peptides that failed for the same reason. The program also shows that a peptide isolated in an academic laboratory in the 1980s can be resurrected as a clinical asset, which is directly relevant to the many research groups holding characterized but abandoned AMPs.
For clinicians, the need is concrete. Carbapenem-resistant A. baumannii is one of the most difficult hospital pathogens, and colistin is among the last-resort drugs still active against it. OMN6's preclinical activity against colistin-resistant isolates matters because it targets the gap beyond the last line of defense. If the Phase IIa data are favorable, the program would offer a new mechanistic class against a WHO critical-priority pathogen at a time when few classes are in development for it.
For manufacturing and the supply chain, OMN6 is a demanding molecule. A 40-residue peptide must be assembled by solid-phase synthesis, oxidized to form the single defined disulfide, purified to pharmaceutical standards, and formulated for delivery to seriously ill hospital patients. Disulfide bond formation at scale raises questions of yield and mispaired linkages, and the cost of goods for a peptide dosed repeatedly in an intensive care setting will determine whether it is commercially viable. The combination of a $25 million Series C and two EU-funded initiatives gives Omnix a realistic run at answering those manufacturing questions before Phase III, the stage where peptide programs have historically foundered as much on cost as on biology.
The current record establishes a great deal about the molecule and almost nothing yet about the medicine. OMN6 has potent, selective, and non-toxic preclinical activity; it has a plausible mechanism; and it has now entered a controlled human trial. Whether it works in patients is unknown, and the company has not disclosed the Phase IIa sample size, duration, or endpoints, nor any interim results.
Several scientific caveats frame these questions. The MIC, selectivity, and toxicity data derive from in vitro and animal studies, not human trials. A disulfide closure is chemically simple, but disulfide bonds are sensitive to reducing environments, and whether the cyclic form survives in the infected lung is a question only human data will answer. The resistance-limiting property of the mechanism is asserted as a hypothesis, not a demonstrated fact, and would require long-term surveillance even after approval to validate.
What would settle the open questions is sequential and mundane: a complete protocol disclosure, the Phase IIa results, a Phase III trial designed around mortality or definitive clinical outcomes, and then, if approved, resistance surveillance in clinical use. None of that guarantees success; the history of antimicrobial peptides is a history of promising preclinical molecules that did not survive contact with patients. But OMN6 is differently positioned. It is a stabilized version of the founding peptide of the field, tested under randomization against a pathogen the WHO has placed at the top of its priority list. The Phase IIa outcome will be informative either way: it will either validate cyclization as a route to new antibiotics or sharpen the definition of what still stands in the way.
Related reading: First Woman Wins Emil Fischer Medal for Synthetic Peptide Research, FDA Panel Backs Six Unapproved Peptides for 503A Compounding List, Copenhagen's New Protein Design Center Opens With 109 Million Dollar Grant, GLP-1 multi-target therapies and manufacturing near 2025 milestones.